Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications

Abhishek R. Keraliya 1,2 · Sree Harsha Tirumani 1,2 · Atul B. Shinagare 1,2 · Nikhil H. Ramaiya 1,2

Received: 3 February 2015 / Revised: 26 March 2015 / Accepted: 31 March 2015 / Published online: 28 April 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Objective The purpose of this article is to provide a comprehensive review of the role of imaging modalities other than PET/CT in the management of Hodgkin lymphoma (HL). PET/CT is the imaging modality of choice in the management of Hodgkin’s lymphoma (HL). However, imaging modalities other than PET/CT such as plain radiographs, ultrasound, CT, MRI and nuclear imaging can help in various stages of clinical management of HL, including the initial workup and post-treatment surveillance. Both CT and MRI help in detecting recurrences, treatment-related pulmonary, cardiovascular and abdominal complications as well as second malignancies. Familiarity with expected post-treatment changes and complications on surveillance images can help radiologists guide patient management. The purpose of this article is to provide a comprehensive review of the role of imaging modalities other than PET/CT in the management of Hodgkin lymphoma (HL).

Main Messages

1. Surveillance of HL patients is usually performed with plain radiographs and CT.
2. Follow-up imaging can depict normal post-treatment changes or treatment-related complications.
3. Imaging is important for the timely detection of second malignancies in HL patients.

Keywords Hodgkin lymphoma · PET/CT · Computed tomography · MRI ultrasound

Introduction

Hodgkin lymphoma (HL) accounts for approximately 10 % of all lymphomas diagnosed in the developed world annually [1]. The WHO classification divides HL into two main types: classical HL (CHL) and nodular lymphocyte predominance HL (NLPHL). CHL is further subdivided into four histological subtypes: nodular sclerosis CHL (NSCHL), mixed cellularity CHL (MCCHL), lymphocyte-rich CHL (LRCHL) and lymphocyte-depleted CHL (LDCHL) [2]. HL has bimodal age distribution with most patients diagnosed between 15 and 30 years of age, followed by another peak in adults over the age of 50. HL is usually confined to the lymph nodes. Cervical and mediastinal lymph nodes are the most common site of lymph nodal involvement in HL. In mediastinal lymph nodes, prevascular and paratracheal subsets are most commonly affected. Isolated infradiaphragmatic lymphadenopathy occurs in less than 10 % of patients at diagnosis [3]. Extranodal involvement is less common in HL than in NHL and seen in only 10–15 % of patients. The most frequent sites of extranodal involvement are bone, bone marrow, lung and liver [4].

HL is now curable in more than 80 % of cases owing to significant therapeutic advances in the form of newer chemotherapeutic drugs, advances in radiotherapy and stem cell transplantation [5]. Treatment for HL usually depends on the stage at diagnosis, histological subtype and prognostic factors. According to National Comprehensive Cancer Network (NCCN) guidelines, the initial evaluation of patients with HL includes detailed history and physical examination, evaluation of performance status, laboratory investigations (blood counts, ESR, LDH, liver and renal function tests) and
radiological investigations (chest radiograph, PET/CT, contrast-enhanced CT). Staging for HL is based on the Cotswolds modification of the Ann Arbor staging system.

Patients with HL are usually classified into four groups: early-stage favourable (stage I–II with no unfavourable factors), early-stage unfavourable (grade I–II with any of the unfavourable factors), advanced favourable (clinical stage III or IV with zero to three adverse risk factors listed below) and advanced unfavourable (clinical stage III or IV with four or more adverse risk factors listed below). Large mediastinal adenopathy (>33 % of the thoracic width on the chest x-ray, ≥10 cm on CT), presence of B symptoms, more than 2 or 3 nodal sites of disease or an ESR of 50 or more are unfavourable prognostic factors for patients with stage I and II disease. Assessment of prognosis is important for formulating management strategies.

For patients with advanced-stage HL, the International Prognostic Factors Project has developed an International Prognostic Index with a prognostic score that is based on the following seven adverse factors: age more than 45 years, male gender, stage IV disease, albumin level below 4.0 g/dl, haemoglobin level below 10.5 g/dl, white blood cell count more than 15,000/mm³, absolute lymphocytic count less than 600/mm³ or a lymphocyte count less than 8 % of the total WBC count [6].

Chemotherapy or combination chemotherapy plus low dose involved field radiation therapy (LD-IFRT) is the standard treatment option in HL. The most common chemotherapeutic regimes used for HL are ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide and prednisone) and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Patients with nonbulky stage IA or IIA disease are considered to have clinical early-stage disease. These patients are candidates for chemotherapy, combined modality therapy or radiation therapy alone [7]. The number of cycles is determined by the pre-treatment prognostic factors (favourable or unfavourable disease) and the rate of response to treatment. The treatment for HL also depends on the patient’s performance state and the response to treatment. ABVD, Stanford V or escalated BEACOPP is the preferred therapy for patients with advanced HL. For patients with refractory HL or who relapse after chemotherapy and involved-field radiation therapy, second-line chemotherapeutic agents, biological therapy (such as rituximab) and autologous stem cell transplant are treatment options. The role of consolidation radiotherapy after chemotherapy in patients with advanced HL is controversial; however involved-field radiotherapy (IF-RT) is beneficial for patients with partial response after chemotherapy according to a prospective randomised trial of 739 patients with advanced HL [8].

Due to improved long-term survival, treatment-related complications have emerged as an important cause of morbidity and mortality in patients with HL. Early and accurate diagnosis of treatment-related cardiovascular and pulmonary complications and second malignancies are of paramount importance to continue the survival benefit in these patients, especially in those treated with mantle field radiation.

Imaging, especially PET/CT, plays a key role in the diagnosis, staging, response assessment, prognostication and surveillance of patients with HL. Though FDG-PET/CT is the imaging modality of choice in HL, other modalities such as conventional radiographs, ultrasound (US), CT and magnetic resonance imaging (MRI) are often used in the evaluation of lymphoma at various stages of management. In this article, we review the role of various imaging modalities beyond FDG-PET/CT in the management of HL with emphasis on imaging features of treatment-related complications.

PET/CT in Hodgkin’s Lymphoma

According to NCCN, 18 F-Fluoro-DeoxyGlucose (FDG) positron emission tomography (PET)/computed tomography (CT) is the corner stone for initial staging and evaluation of treatment response in HL. Response to treatment with chemotherapy or combined modality therapy is assessed by restaging with FDG-PET/CT at midcycle (interim PET/CT) or completion of treatment. FDG-PET positivity at the treatment completion is an adverse prognostic factor for disease-free survival [9]. Metabolic imaging with PET often leads to either upstaging or downstaging in approximately 15–40 % of patients with Hodgkin lymphoma with impact on management in about 5–15 % [10, 11]. Several studies have established the role of interim FDG-PET in the prognosis of HL during chemotherapy. PET is particularly useful in the evaluation of a post-treatment residual mass in patients after the completion of therapy, with positive FDG-PET associated with a significantly poorer progression-free survival [12]. Negative interim FDG-PET/CT is highly predictive of progression-free survival, even more than the International Prognostic Score (IPS) [13, 14]. According to a prospective study, the sensitivity and specificity of FDG PET to predict relapse are 79 % and 97 %, respectively, with a negative predictive value more than 90 % in HL patients after the completion of chemotherapy [15]. Negative PET study reliably rules out disease relapse. However, the positive predictive value of PET is variable, which is an important limitation of PET, and a biopsy is necessary to confirm the diagnosis of a relapse [16]. FDG-PET/CT is also useful in radiation treatment planning and helps in better delineation of the radiation field without increasing radiation volumes [17]. There are some important limitations of FDG-PET/CT. FDG uptake can also be seen in post-treatment inflammation, infection, brown fat and normal physiologic
metabolic activity, which can lead to false-positive results. Similarly, low-grade histological subtypes and minimal residual disease can give false-negative results.

**Imaging beyond PET at initial staging**

The most typical presentation of HL is painless, enlarged superficial lymphadenopathy with systemic symptoms such as fever, night sweats, fatigue and weight loss. Patients with intrathoracic lymphadenopathy may present with respiratory symptoms such as cough, dyspnoea and chest pain. Chest radiography can be performed as the initial investigation in these patients. Chest X-ray provides preliminary information about involvement of the mediastinum and lungs. Bulky mediastinal lymphadenopathy at diagnosis is an unfavourable prognostic factor in patients with HL and can be quantified by measuring using the mediastinal mass ratio. Cotswolds modification of the Ann Arbor staging system defines bulky disease as a mediastinal mass exceeding one third of the intrathoracic transverse diameter of the thorax at the T5/6 intervertebral disc level on a posteroanterior chest radiograph (Fig. 1) [18]. US is often helpful in confirming enlarged nodes and guiding biopsy, particularly cervical lymph nodes, the most common nodal group affected in patients with HL. US can be useful for evaluation of extranodal sites of involvement in the abdomen (e.g., gallbladder, kidney) and image-guided biopsy of focal lesions in solid organs such as the liver and spleen [19].

CT can be performed for further evaluation of abnormalities detected on chest X-ray. CT can help in depicting other areas of lymph node enlargement that are not obvious on chest radiographs. On CT, HL is characterised by the presence of a discrete anterior mediastinal mass with a lobulated contour with homogeneous soft-tissue attenuation. Large lymph nodal masses can have a heterogeneous appearance with low attenuation areas representing necrosis, haemorrhage or cystic degeneration (Fig. 1). CT is particularly useful for exact anatomical delineation of lymph nodal involvement and in formulating treatment plans and radiation fields.

Although PET/CT remains the corner stone for initial staging and response assessment at the completion of treatment in patients with HL, MRI plays an important part in management of patients with HL. The role of MRI is particularly important in paediatric and younger patients because of exposure to ionising radiation in diagnostic modalities such as CT and PET/CT. In recent years, diffusion-weighted imaging (DWI) has been emerging as a radiation-free alternative to PET/CT for staging of various malignancies including lymphoma [20]. DWI is a functional MRI technique that depicts differences in the mobility of water in tissues. Hypercellular tumours exhibit more restricted water diffusion than normal tissues, which is reflected as high signal intensity on DWI with low apparent diffusion coefficient (ADC) values. DWI-MRI has sensitivity up to 97 % and is a feasible alternative to PET/CT for follow-up and treatment response assessment in patients with FDG-avid lymphoma [21, 22]. The whole body-DWI technique does not need specific equipment and is well tolerated by patients thanks to the relatively shorter acquisition time, which is longer than the acquisition time for CT but shorter than for PET/CT. The use of higher magnetic field strength (3 T) has a higher signal-to-noise ratio (SNR), which improves the ability of lesion detection. The cost of a WB-MRI is roughly equal to the cost for an 18F-FDG PET/CT examination. MRI is also useful in evaluation of intracranial disease and spinal cord involvement because of better soft tissue resolution. In the thorax, MRI is beneficial for assessment of chest wall, vascular, cardiac and pleural and brachial plexus involvement [23].

Central venous thrombosis and compression: Superior vena cava (SVC), brachiocephalic or internal jugular veins can be directly compressed by the mediastinal adenopathy with development of SVC syndrome. Lymphoma is responsible for about 10 % of malignant SVC obstruction cases [24]. SVC and brachiocephalic venous thrombosis can also complicate chemotherapy catheter placement in patients with HL. Contrast-enhanced chest CT is the modality of choice for evaluation of SVC obstruction and to differentiate between venous thrombosis and extrinsic compression. Chest wall venous collaterals and characteristic focal hyperenhancement of liver (“hot-spot sign”) is seen with SVC or brachiocephalic vein obstruction due to opening of caval-mammary-phrenic–hepatic capsule-portal pathways (Fig. 1). In this pathway, blood flows from the internal mammary vein to the inferior phrenic vein. The inferior phrenic vein then communicates with hepatic capsular veins, which in turn drain into the intrahepatic portal tributaries. Focal non-mass-like contrast enhancement is seen along the superior aspect of the liver with dilated inferior phrenic veins and hepatic capsular veins [25, 26].

Central nervous system (CNS) involvement in HL is rare with an overall reported incidence of 0.2–0.5 % [27]. Intracranial HL is usually seen in patients with relapsed and progressive disease as a part of widespread systemic involvement. The most common histological subtypes of HL associated with CNS involvement are MCHL and NSHL. Evaluation of CNS involvement in HL on FDG-PET is limited by the intense physiologic FDG uptake in the brain. CT with intravenous contrast and MRI are useful in such instances. Spinal cord compression is a rare complication of HL, occurring usually in the setting of progressive and advanced disease. As the initial symptom of HL, it is extremely rare, with only a few cases reported in the literature [28]. Prompt diagnosis is crucial as early surgical decompression, radiation therapy and chemotherapy are imperative to prevent irreversible neurological deficits. MR imaging of the spine, without and with the use of gadolinium-based contrast material, is...
the standard for the diagnosis of malignant spinal cord compression (Fig. 2) [29].

**Imaging beyond PET during follow-up**

Due to the long-term risks and complications of the therapies of HL, regular follow-up of treated patients with HL is important. The follow-up schedule depends on the age of patients, staging at the time of diagnosis and type of treatment given. Physical examinations and blood tests are performed every 3 to 6 months for the first 2 years, then every 6 to 12 months for the next 3 years and then annually [30]. The NCCN guidelines recommend imaging techniques such as chest radiographs or chest CT and abdomen and pelvis CT to be performed every 6 months for the first 2 years and then annually for the next 3 years. If the neck is involved in the radiation treatment field, thyroid function tests are performed annually. The overall 5-year survival rate for early-stage HL in children and adolescent population is more than 90% [31]. However, up to 10% of patients with early-stage and up to 25% patients with advanced-stage HL relapse after first-line therapy [32]. In addition to detecting long-term treatment-related complications, the goal of the surveillance scans is to detect local and distant recurrences of lymphoma. Recurrent lymphoma has the same appearance as primary HL; however pulmonary parenchymal involvement is more common in recurrent HL. The various patterns of parenchymal involvement include a pulmonary nodule or mass, lobar or segmental consolidation with an air bronchogram and a reticular pattern with peribronchovascular and interlobular septal thickening [33]. Findings suggestive of recurrent disease in the radiation field include an alteration in the contour of the radiation fibrosis with an increase in size, convex borders, appearance of homogeneous opacity with obliteration of the air bronchogram and filling of the bronchi (Fig. 3) [34].

Restaging CT examinations often demonstrate findings that represent expected post-treatment changes. Dystrophic lymph...
nodal calcification is seen in approximately 2–8 % of treated patients with HL following radiation or chemotherapy (Fig. 4). Lymph nodal calcification in untreated patients is seen in less than 1 % of patients with aggressive histological subtypes of HL [35]. In treated patients, dystrophic calcification represents treatment-induced necrosis and is associated with good prognosis and long-term survival [36]. Absence of spleen is another finding on imaging that can be encountered in patients with HL. Before effective chemotherapy and radiotherapy were available and staging was crucial to differentiate limited-stage disease from extensive-stage disease, splenectomy was often performed in patients with HL as 20–35 % with clinically limited disease confined to above the diaphragm will have occult splenic involvement [37].

Rebound hyperplasia of the thymus occurs in 10 to 25 % of patients treated with chemotherapy [38]. Thymic rebound usually occurs 1 to 11 months after completion of chemotherapy because of reactive lymphoid hyperplasia in response to withdrawal of chemotherapy and is usually self-limiting and reversible [39]. It is important to differentiate thymic rebound from recurrent mediastinal disease. CT features that favour thymic regrowth over lymphomatous thymic involvement or thymic tumour are a diffusely enlarged thymus that maintains the normal thymic morphology with a smooth contour, uniform density without invasion of adjacent tissues and absence of pericardial or pleural effusion (Fig. 5).

Until the 1990s in the prechemotherapy era, radiation therapy was often used as a single modality in the treatment of HL with more extended fields and higher doses than in current radiotherapy techniques [40]. In patients who have received infradiaphragmatic radiotherapy, various abdominal organs could be affected by side effects of radiation. Radiation-induced liver disease (radiation hepatitis) has a threshold of 30–35 Gy for the whole liver. Radiation-induced liver injury demonstrates an acute phase occurring within 3 months of exposure characterised by hyperaemia, venous congestion
and fatty infiltration and a chronic phase with development of fibrosis and architectural distortion. On CT it appears as a sharply demarcated area of hypodensity corresponding to the radiation ports; however, in case of background fatty infiltration of liver, the irradiated area appears hyperdense compared to adjacent liver parenchyma. Radiation-induced pancreatic injury is characterised by parenchymal atrophy and fibrosis. The spleen is also radiosensitive and splenic atrophy occurs at doses of 35–40 Gy [41]. The upper poles of the kidneys (more commonly the left kidney because of its higher anatomical position than the right) can be affected by radiation. Radiation-induced cortical thinning and atrophy of the upper poles of the kidneys are well demarcated from the rest of the renal parenchyma and frequently seen on follow-up studies in patients with HL (Fig. 6) [42]. Uncommonly, lymphomatous involvement in the abdomen and pelvis can fistulise with the gastrointestinal tract resulting in tumour-bowel fistula (TBF). TBF can occur either spontaneously or following treatment with radiotherapy or chemotherapy. Gastroesplenic fistula can occur in association with gastric or splenic lymphoma and clinically manifests with epigastric pain and upper gastrointestinal bleeding [43, 44]. CT is the investigation of choice for the diagnosis of TBF with demonstration of a tract following oral contrast administration (Fig. 7).

Radiation therapy causes destruction of haematopoietic marrow elements and their replacement by fatty marrow elements usually occurring 3 to 6 weeks following radiotherapy; this is characterised by fatty replacement of marrow and manifests on MRI as T1 hyperintensity with a sharp demarcation corresponding to the radiation port [45]. Bone marrow recovery after radiation therapy can be reversible or irreversible depending on the amount of radiation given. Partial or complete recovery usually occurs at low doses (less than 30 Gy). Permanent fatty marrow replacement is usually seen above the dose of 36 Gy with very little chance of complete recovery [46].

Complications of treatment

The main cause of increased mortality and morbidity among long-term survivors of HL are treatment-related development of secondary cancers, drug-related toxicities, radiation-induced pulmonary, cardiovascular and abdominal complications, thyroid disorders and myelosuppresion.

Cardiovascular toxicity Cardiovascular toxicity in treated patients with HL can be due to doxorubicin and/or radiation. The cause-specific mortality for cardiovascular disease is approximately 10% [47]. The cumulative incidence of adverse cardiac events in patients treated for HL is more than 20% 25 years after radiotherapy and prior mediastinal radiation is a long-term risk factor for increased cardiovascular mortality and morbidity in HL patients, especially with doses above 30 Gy [48, 49]. Radiation produces dose-dependent cardiac damage through several different mechanisms. Radiation-induced cardiovascular complications can be acute, such as acute pericarditis, or chronic, such as coronary artery disease, valvular heart disease, decreased ventricular function, arrhythmia and chronic pericarditis. Initial evaluation of coronary artery disease is done with stress echocardiography or nuclear scintigraphy to look for inducible ischaemia. Patients with a

---

Fig. 4 A 37-year-old male with a history of HL treated with chemotherapy and mediastinal radiation 5 years ago. Axial contrast-enhanced CT image reveals anterior mediastinal lymphadenopathy with peripheral calcification (arrows).

Fig. 5 A 22-year-old male with relapsed HL shows thymic rebound after second-line chemotherapy. a Axial non-contrast CT image shows triangular low-attenuation anterior mediastinal soft tissue (arrow) suggestive of normal thymus. b Axial non-contrast CT image after 3 months of chemotherapy shows diffusely enlarged thymus (arrow). c Axial non-contrast CT image 4 months after completion of chemotherapy shows resolution of thymic enlargement with similar appearance of thymus compared to pretreatment study.

Fig. 6 The thymic contour is maintained with smooth margins and absence of surrounding vascular invasion. a Axial non-contrast CT image 4 months after completion of chemotherapy shows resolution of thymic enlargement with similar appearance of thymus compared to pretreatment study.
positive stress test can be further evaluated with coronary CT angiography. Coronary calcifications are frequently visualised at follow-up chest CT in patients with treated HL (Fig. 8). Patients treated with radiation therapy are also at higher risk for development of noncoronary arteriosclerotic vascular disease including subclavian and carotid artery stenosis (Fig. 8). In a retrospective study of 414 patients treated with radiation therapy, Hull et al. found the incidence of noncoronary atherosclerotic disease was 2 % at 5, 3 % at 10 and 7 % at 20 years [50]. Radiation-induced pericardial disease can manifest in the form of pericarditis or pericardial effusion and is seen in 20 to 40 % of patients treated with mantle field radiation [51]. Echocardiography and MRI are useful modalities for the evaluation of pericardial disease. Radiation-induced valvular disease can manifest as both stenosis and insufficiency.

Anthracyclines cause dose-dependent cardiac toxicity that can produce irreversible cardiomyopathy. Left ventricular dysfunction has been reported to occur in 5 % of patients at cumulative doses as low as 240 mg/m$^2$ [52]. Monitoring of left ventricular function with echocardiography, radionuclide angiography or less commonly cardiac MRI is recommended in patients who have received anthracycline-based chemotherapy. A multiple-gated acquisition (MUGA) scan is particularly useful for determination of the ejection fraction in HL patients before and after they undergo chemotherapy. A 10 % decline of the left ventricular ejection fraction (LVEF) below the lower limit of normal or an absolute decline of 45 % or decline of 20 % at any level is indicative of cardiac function deterioration. The risk of cardiac toxicity increases with combined treatment (doxorubicin and radiation) compared to either treatment given alone [48, 53, 54].

**Pulmonary toxicity** Like cardiovascular toxicity, pulmonary toxicity in HL patients can be due to radiotherapy or cytotoxic chemotherapy.

**Radiation-induced pulmonary toxicity** Newer radiotherapy techniques such as involved-site radiation therapy (ISRT) and intensity-modulated radiation therapy (IMRT) deliver less radiation to uninvolved normal organs compared to conventional involved-field or extended-field radiation therapy and reduce the long-term pulmonary and cardiovascular toxicity [55]. The degree of radiation damage depends on multiple factors such as the total radiation dose, fractionation, dose rate, volume of the lungs receiving a specified dose and beam arrangement [56].

Radiologic manifestations are usually confined to the lung tissue within the radiation port and are dependent on the
interval after completion of treatment. Radiation-induced lung injury is divided into two clinical stages: the early stage characterised by radiation pneumonitis and late stage characterised by chronic radiation fibrosis. Early radiation pneumonitis usually occurs about 4–12 weeks after completion of radiation therapy and is characterised by ground-glass opacification, consolidation and atelectasis within the radiation portals. Radiation fibrosis usually develops within 6–12 months after completion of radiation therapy. Typical features of radiation fibrosis include a well-demarcated area of volume loss, linear scarring or consolidation, parenchymal distortion and traction bronchiectasis, ipsilateral mediastinal shift and adjacent pleural thickening [34, 57].

**Bleomycin- and cyclophosphamide-induced pulmonary toxicity** Bleomycin is commonly used in chemotherapy regimens of HL. Bleomycin-induced lung injury usually occurs in 3%–20% of treated patients [58]. HRCT is more sensitive than chest radiographs in identifying bleomycin-induced lung abnormalities. Common manifestations of bleomycin-induced lung disease are diffuse alveolar damage, nonspecific interstitial pneumonia (NSIP) and bronchiolitis obliterans organising pneumonia (BOOP) (Fig. 9). Cyclophosphamide can cause pulmonary haemorrhage and diffuse alveolar damage. CT manifestations of NSIP include patchy ground-glass opacities combined with reticular opacities in peripheral subpleural distribution. BOOP is characterised by bilateral asymmetrical ground-glass opacities or airspace consolidation in a peripheral or peribronchial distribution [59, 60].

**Second malignancies** Second malignancies are the leading cause of death in long-term survivors of HL. Risk factors depend on the type of second malignancy and include the radiation dose and field, chemotherapy agents and doses administered, history of smoking and sex and age of the patient [61]. The maximum risk of a second cancer is at 5 to 9 years after chemotherapy alone, but after combined modalities the risk remains for 25 years or longer [62]. Solid tumours account for more than 50% of second malignancies developing after 15 or more years of follow-up in patients treated for HL [63]. Lung and breast cancers are the most common secondary cancers in patients with HL due to their proximity to the radiation portal (Fig. 10a) [64]. Other solid tumours that have an increased incidence among HL survivors include gastrointestinal cancers, bone and soft tissue tumours, thyroid cancers, malignant melanoma, bladder cancer and malignant mesothelioma. The risk of developing secondary cancer is lower with combined modality treatment than with radiotherapy alone as the initial treatment [61, 63, 65, 66].

---

**Fig. 8** Cardiovascular complications. **a** A 38-year-old female with a history of nodular sclerosing HL at the age of 12 treated with chemotherapy and upper mantle radiation. Axial non-enhanced CT image shows mitral valve calcification (arrow). Note the bilateral mastectomies with a breast prosthesis from prior breast cancer. **b** A 40-year-old female with a history of nodular sclerosing HL at the age of 15 treated with chemotherapy and upper mantle radiation. Digital subtraction angiogram of the left carotid artery shows moderate to severe narrowing of the left distal common carotid artery (arrow). **c** Coronal reformatted image of contrast-enhanced CT during follow-up shows the presence of a stent in the left common carotid artery (arrow). Note the presence of aortic arch and right coronary artery calcifications (arrowheads). Also note the absence of spleen from the prior splenectomy.

**Fig. 9** A 22-year-old male with nodular sclerosing HL on treatment with an ABVD regimen and complaining of new onset cough without fever. Axial contrast-enhanced lung window CT image shows patchy ground-glass opacities in the right lower lobe with peripheral subpleural distribution suggestive of drug toxicity.
The risk of lung cancer is substantially increased in patients with HL treated with radiotherapy or chemotherapy, especially among smokers. The overall survival of non-small-cell lung cancer (NSCLC) in the setting of treated HL is inferior compared to patients with de novo lung cancer [67]. Breast cancers after HL typically occur after a long latency of 10–15 years and are associated with young age at irradiation. Annual breast screening (mammography or MRI) beginning no later than 8 to 10 years after treatment completion or at age 40 (whichever occurs earlier) is recommended for woman who have received chest or axillary radiation [68].

Patients with HL have a 20-fold increased risk of mesothelioma after radiotherapy. Mesothelioma arises from the mesothelial cells forming the serosal membranes of body cavities. Pleural and peritoneal cavities are frequent sites of involvement. Patients with lymphoma-associated malignant mesothelioma have younger age at diagnosis and longer overall survival compared with those with asbestos-associated mesothelioma [69]. CT is the primary imaging modality used for the evaluation of malignant pleural mesothelioma. Pleural mesothelioma presents as pleural thickening, pleural-based nodules, pleural effusion, thickening of interlobular fissures and pleural calcifications. The tumour frequently causes invasion of the chest wall, pericardium, heart and diaphragm. MRI is particularly helpful in detecting chest wall and mediastinal involvement because of the improved soft tissue contrast resolution [70, 71]. The CT features of malignant peritoneal mesothelioma are peritoneal- or omental-based masses as well as irregular or nodular peritoneal thickening with or without ascites (Fig. 10b) [72].

Radiotherapy is the main cause of thyroid cancers after HL, since the thyroid gland is a highly radiosensitive organ and is frequently exposed to radiation because of its location in neck (Fig. 10c). The risk of developing various thyroid abnormalities such as thyroid cancer, Grave’s disease, thyroiditis, hypothyroidism, nodular thyroid disease and thyroid atrophy is more than 50 % in patients with HL [40, 73, 74].

Patients with HL who received subdiaphragmatic radiotherapy have a dose-dependent increased risk of gastric cancer. The risk is further increased in patients who also received...
Chemotherapy with MOPP (mechlorethamine, vincristine, procarbazine and prednisone) or BEACOPP regimes containing procarbazine. The stomach cancer risk is also increased in patients who are treated with dacarbazine, a component of the ABVD regimen, frequently used in patients with HL [75].

Radiation-induced sarcoma (RIS) is rare and associated with higher doses of radiation and with the use of concurrent chemotherapy (Fig. 10d). The mean latency period for post-radiation bone and soft tissue sarcomas ranges from 4 to 17 years [76]. Post-radiation sarcoma usually arises in or near the radiation field [77].

Imaging plays an important role in the timely detection of second malignancies in patients with HL. Knowledge of the history and site of prior radiotherapy can help the radiologists to increase the index of suspicion of second malignancies.

Conclusion

In conclusion, although PET/CT remains the cornerstone for initial staging and response assessment at the completion of treatment in patients with HL, imaging modalities other than PET/CT often help in the initial workup of patients with HL. Treatment for HL usually depends upon the stage at diagnosis, histological subtype and prognostic factors, and chemotherapy or combination chemotherapy plus low-dose involved-field radiation therapy (LD-IFRT) is the standard treatment option in HL. Treatment response is assessed by restaging PET/CT using the Deauville criteria. Surveillance of HL patients after treatment is performed with plain radiographs and CT. Follow-up imaging can depict normal post-treatment changes or complications including second malignancies. Familiarity with expected post-treatment changes and complications on surveillance scans can help radiologists to guide patient management.

Disclosures  A.B. Shinagare was awarded an RSNA research grant starting in July 2014. No disclosures are reported for the remaining authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References


